Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.
Precigen, Inc. (Nasdaq: PGEN) is a biopharmaceutical company focused on precision medicines, and its news flow reflects the transition from a clinical-stage organization to a commercial-stage company. Recent announcements highlight full FDA approval and commercial launch of PAPZIMEOS (zopapogene imadenovec-drba), which the company describes as the first and only FDA-approved therapy for adults with recurrent respiratory papillomatosis (RRP). News items detail how PAPZIMEOS was discovered and designed using Precigen’s AdenoVerse platform and how it is being prescribed nationwide in the United States.
Investors and observers following PGEN news will see updates on PAPZIMEOS commercialization, including patient hub enrollment, payer coverage across private health plans and government programs, manufacturing and supply chain arrangements, and engagement with major medical centers and community practices. The company also issues news on long-term clinical data for PAPZIMEOS, emphasizing durable complete responses, reductions in surgery rates, and safety outcomes presented at medical meetings and in peer-reviewed publications.
Beyond PAPZIMEOS, Precigen’s news coverage includes pipeline developments such as progress in Phase 2 trials for PRGN-2009 in HPV-associated cancers and updates on PRGN-3006, an investigational UltraCAR-T therapy for acute myeloid leukemia and myelodysplastic syndromes. Financial results releases and related press statements provide context on capital resources, non-dilutive financing arrangements, preferred stock transactions, and the company’s expectations regarding funding operations through a projected cash flow break-even point.
Visitors to the PGEN news page can expect regular disclosures on regulatory milestones, conference presentations, investor webcasts, and business updates that illustrate how Precigen is advancing its precision medicine strategy and commercial execution around PAPZIMEOS and its broader pipeline.
Precigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company focusing on gene and cell therapies, announced that its CEO, Helen Sabzevari, PhD, will present a corporate and clinical overview at the 41st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 3:45 PM PT in San Francisco, California. Participants can register to view the event on Precigen's website under the Events & Presentations section. Precigen is advancing therapies in immuno-oncology and other critical areas, working towards innovative solutions in biotherapeutics.
Precigen announced positive Phase 1 data for PRGN-3006 UltraCAR-T at the ASH Annual Meeting. The treatment showed a 27% objective response rate (ORR) in heavily pre-treated relapsed/refractory acute myeloid leukemia (AML) patients following lymphodepletion. Notably, 60% of patients experienced a decrease in bone marrow blasts. The therapy was well-tolerated with no dose-limiting toxicities reported, highlighting its safety profile. PRGN-3006 has received both Orphan Drug and Fast Track Designations from the FDA, underscoring its potential in addressing critical cancer treatment gaps.
Precigen, Inc. (Nasdaq: PGEN) reported a significant revenue increase of over 200% to $13.4 million for Q3 2022, driven by collaboration and licensing agreements. The company has retired $144 million of convertible notes, saving $5.4 million in interest. Ongoing clinical trials include PRGN-2012 for recurrent respiratory papillomatosis, and data will be showcased in January 2023. Cash reserves were reported at $153.8 million as of September 30, 2022. Precigen remains focused on its gene and cell therapy pipeline, indicating a substantial cash runway into Q4 2023.
Precigen, Inc. (Nasdaq: PGEN) will announce its third quarter 2022 financial results after market close on November 9, 2022. A conference call to discuss the results will be held at 4:30 PM ET on the same day. Participants can join by dialing 1-888-317-6003 (US), 1-866-284-3684 (Canada), or 1-412-317-6061 (International) with access code 3010378. Precigen focuses on gene and cell therapies, targeting diseases in immuno-oncology, autoimmune disorders, and infectious diseases.
Precigen, Inc. (Nasdaq: PGEN) has appointed Rutul R. Shah as Chief Operating Officer (COO), effective October 1, 2022. Shah, who joined the company in 2014, will oversee strategic management of the company’s portfolio to enhance operational efficiency. With over 17 years in the biopharmaceutical industry, he brings significant expertise in gene and cell therapies. Precigen focuses on innovative treatments in immuno-oncology and other areas, aiming to advance its clinical pipeline. The company, led by President and CEO Helen Sabzevari, emphasizes a commitment to precision medicine.
Precigen, a biopharmaceutical company focused on gene and cell therapies, announced that its President and CEO, Helen Sabzevari, will participate in a fireside chat at the 2022 Wells Fargo Healthcare Conference in Boston, Massachusetts. The event is scheduled for September 7, 2022, at 11:35 AM ET. Precigen aims to improve patient lives through innovative therapies targeting urgent diseases, including areas like immuno-oncology and autoimmune disorders. More details regarding the conference can be found on their official website.
Precigen (Nasdaq: PGEN) announced the sale of its non-healthcare subsidiary, Trans Ova Genetics, for $170 million in upfront cash, plus an additional $10 million contingent on performance over the next two years. The proceeds will be utilized to pay senior convertible notes, aiming to enhance the company's financial position. This strategic move reflects Precigen's focus on its core operations in gene and cell therapies, enhancing shareholder value while streamlining its business portfolio.
Precigen (Nasdaq: PGEN) announced the completion of multiple Phase 1 clinical trials for its UltraCAR-T and AdenoVerse™ therapies, aimed at treating various cancers and conditions. A significant financial move includes the agreement to sell its subsidiary Trans Ova Genetics for $170 million, enhancing its balance sheet. As of June 30, 2022, Precigen reported cash reserves of $132.8 million. For the second quarter, total revenues fell 24%, leading to a loss from continuing operations of $26.1 million. However, the company remains optimistic, citing progress in key clinical programs and expected data presentations.
Precigen (Nasdaq: PGEN) will announce its second quarter and first half 2022 financial results after market close on August 8, 2022. A conference call is scheduled for 4:30 PM ET the same day to discuss these results and provide a business update. The company specializes in gene and cell therapies targeting immuno-oncology and other diseases. Precigen aims to innovate affordable biotherapeutics and advance its clinical pipeline.
Precigen has announced a definitive agreement to sell its non-healthcare subsidiary, Trans Ova Genetics, to URUS for $170 million in upfront cash, plus up to $10 million in earn-outs over two years. The sale aims to solidify Precigen's balance sheet, allowing payment of senior convertible notes due in July 2023. This divestiture aligns with Precigen's strategy to focus exclusively on healthcare, enhancing the development of its gene and cell therapies for serious diseases.